• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail

ANADA 200-118 Neomycin Oral Solution - supplemental approval (July 14, 1998)

Approval Date: July 14, 1998

I. GENERAL INFORMATION:

NADA200-118
Sponsor:Phoenix Scientific, Inc.
3915 S. 48th St. Terrace
St. Joseph, Missouri 64506-0457
Generic Name:Neomycin Sulfate
Trade Name:Neomycin Oral Solution
Marketing Status: 
Effect of Supplement:To revise the withdrawal period to 1 day in cattle, 2 days in sheep, and 3 days for swine and goats to be identical to pioneer product.
  1. Established Name: neomycin sulfate
  2. Trade/Proprietary Name: Neomycin Oral Solution
  3. Dosage Form: oral solution
  4. How Supplied: 473.1 mL (pt). 3.785 L (1 gal)
  5. How Dispensed: OTC
  6. Amount of Active Ingredients: 200 mg of neomycin sulfate per mL (140 mg neomycin base per mL)
  7. Route of Administration: Orally in drinking water or milk
  8. Species: Cattle (excluding veal calves), Swine, Sheep, and Goats.
  9. Labeled Dosage: 10 mg/lb body weight daily in divided doses for a maximum of 14 days
  10. Indication for Use: For the treatment and control of colibacillosis (bacterial enteritis) caused by Escherichia coli susceptible to neomycin sulfate.
  11. Effect of Supplement: To revise the withdrawal period to 1 day in cattle 2 days in sheep, and 3 days for swine and goats to be identical to pioneer product.
  12. Pioneer/NADA #: Pharmacia & Upjohn, NeomixÒ 325, NADA 11-315

 

II. TARGET ANIMAL SAFETY AND DRUG EFFECTIVENESS

No new data were required for the approval of this supplement. The basis for this supplemental approval is in the original approval of this ANADA which was approved on November 29, 1994.

 

III. HUMAN FOOD SAFETY

Based on the formulation characteristics of the pioneer and generic products, Phoenix Scientific, Inc. was granter a waiver from conducting an in vivo bioequivalence study when the original ANADA was approved on November 29, 1994. Since that approval, the pioneer Pharmacia & Upjohn, has supplemented their application to change the withdrawal periods for their product, NeomixÒ 325. Phoenix Scientific is supplementing their ANADA with a labels identical to the pioneer labels.

 

IV. AGENCY CONCLUSIONS

This supplemental application submitted under section 512( b) of the Federal Food, Drug, and Cosmetic Act, satisfies the requirements and demonstrates that Neomycin Oral Solution when used under it proposed conditions of use, is safe and effective for the labeled indications and revised withdrawal periods. The withdrawal periods have been changed to 1 day in cattle, 2 days in sheep, and 3 days for swine and goats.

Under the Center’s supplemental approval policy, this is a Category II change [21 CFR 514.106(b)(2)(xi)]. The approval of this change is not expected to have any adverse effect on the safety or effectiveness of this new animal drug. The change allows for a decrease in the withdrawal period. Accordingly, this approval did not require a reevaluation of the safety or effectiveness data in the parent application.

 

V. LABELING